163 results on '"Bokemeyer, C."'
Search Results
2. 7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis
3. P50 Joint Modelling of Intermediate Longitudinal Biomarkers to Predict Overall Survival in Patients with Solid Tumors
4. Non-seminomatous testicular germ cell tumours with teratoma-free primaries exhibit a superior early relapse-free survival
5. Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trial
6. LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours
7. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
8. PO-31: The small-molecule FXIa inhibitor, BMS-26208, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression
9. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
10. 104P Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
11. Supportive care in patients with cancer during the COVID-19 pandemic
12. Immunophenotyping of tumor-infiltrating T cells in primary CNS lymphoma
13. 626P Cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice: Interim analysis of the non-interventional SCOPE study
14. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database
15. Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy
16. An individual patient data (IPD) prognostic factor study on the value of pathological factors in clinical stage I seminoma testis patients under active surveillance from the EAU Testicular Cancer Guidelines panel
17. Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3
18. Cisplatin resistance in germ cell tumours: Biological mechanisms and therapeutic avenues
19. Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”
20. Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)
21. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
22. Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic stratification
23. Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC): Interim results of the non-interventional SCOPE study
24. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
25. EP-1618: Monoubiquitinylated histone H2B as a potential target in treatment resistant germ cell tumors
26. Assessing the Need for Palliative Care in LVAD and HTX Patients
27. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: A systematic review by the Testicular Cancer Guidelines Panel
28. Proof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study)
29. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study)
30. Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer
31. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
32. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
33. Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study
34. Anxiety and depression in long-term testicular germ cell tumor survivors
35. Treatment of Advanced Germ Cell Tumours by Dose Intensified Chemotherapy with Haematopoietic Growth Factors or Peripheral Blood Stem Cells (PBSC)
36. 1596 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk calculator (MONITOR-GCSF study)
37. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
38. P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy
39. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
40. Advances in the Treatment of Metastatic Germ Cell Cancer and Colorectal Cancer in Recent Years
41. Poseidon Phase I/II Trial: Abituzumab Combined with Cetuximab Plus Irinotecan As Second-Line Treatment for Patients with Kras Wild-Type Metastatic Colorectal Cancer
42. Folfoxiri + Bevacizumab (Bev) in Patients (Pts) with Previously Untreated Metastatic Colorectal Cancer (Mcrc): Final Survival and Pharmacogenomic Profiling Results from the Opal Study
43. Brain Metastases in Male Germ Cell Tumors (Gct): a Large Retrospective Analysis on Behalf of the Swenoteca and the G3 Consortium
44. Outcome According to Tumor Ras Mutation Status in Opus Study Patients with Metastatic Colorectal Cancer Randomized to FOLFOX4 with or Without Cetuximab as First-Line Treatment
45. Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial
46. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
47. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
48. Marine Alkaloid Monanchocidin: A Proteomic-Based Screening of Protein Targets in Cisplatin-Resistant Tumor Cells
49. Poster session 3. Drug profiles - preclinical
50. Early Tumor Shrinkage and Clinical Outcome in Metastatic Colorectal Cancer: Analysis of Predictive Utility in the CRYSTAL and OPUS Studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.